Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia

Endalamaw Tesfa1*, Daniel Siefu2, Yididya Belayneh2 and Zewdie Mekonnen1

Abstract

Objective: HAART had significantly improved the quality of life of HIV patients. However, it results different adverse effects such as: hepatotoxicity, nephrotoxicity, lipodystrophy, anemia, diarrhea, psychiatric disorder and others. Therefore, this comparative cross sectional study was designed to investigate liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital.

Result: A total of 152 individuals (76 cases and 76 controls) were included in this study. The mean ages of treatment and control groups were 37.37 and 36.38 respectively. The mean values of liver enzymes (ALT, AST and ALP), total bilirubin and direct bilirubin were significantly higher (p < 0.05) while, total protein and creatinine were significantly lower in patients taking HAART compared with treatment naïve controls. In this study, about 19 (25%) of clients in HAART treated groups and 7 (9.2%) of treatment naïve controls had showed liver enzyme changes. Moreover, 23.7% and 1.3% of the HAART treated groups developed mild and moderate liver enzyme elevation or hepatotoxicity, respectively. In this study, significant difference was observed in liver enzyme elevation between ART and pre-ART patients. As a result, regular clinical and laboratory monitoring of liver function will be necessary to prevent severe form of liver injury.

Keywords: HAART, HIV, Liver enzyme elevation, Hepatotoxicity, Debre Berhan

Introduction

Highly active antiretroviral therapy (HAART) had significantly improved the quality of life of patients infected with human immunodeficiency virus (HIV) [1]. Despite, this positive effect, HAART give rise to adverse effects that lead to discontinuation of the treatment [2]. Adverse drug reactions might be asymptomatic or symptomatic. Symptomatic adverse effects may results in treatment failure, drug resistance and regimen change [1, 2]. Different drugs had distinct adverse effects. Patients getting stavudine (d4T) and protease inhibitor (PI) containing regimen were reported to develop lipodystrophy, insulin resistance and accelerated bone loss [3]. Patients receiving nevirapine containing regimen also developed liver toxicity and skin rash [4–6]. Similarly, Patients taking efavirenz containing regimen were also reported with psychiatric problem and night mares [7–9]. Zidovudine (AZT) also has been found to cause anemia and bone marrow suppression, and some ARV drugs were also reported to cause nephrotoxicity and lactic acidosis [1, 2].

Liver enzyme elevation is common problem that encounter in patients taking HAART. Antiretroviral
(ARV) drugs damage the liver cells by direct toxicity of the drug or from its active metabolites. Duration of therapy and onset of liver disease provided a clue to the cause of liver injury. Liver injuries may be predictable or unpredictable. In case of predictable liver injury, toxicity might be related with the dose of the drug [10, 11]. From different studies the incidence of liver injury was different among different populations and different drug combinations [12]. In Ethiopia a study conducted at Debre Tabor hospital, the magnitude of abnormal liver enzymes in patients taking HAART and on pre-ART patients was 20.1% and 22% respectively. The study reported higher mean ALT level in patients taking HAART compared to pre-ART patients [13]. In another study conducted in Cameroon the incidence of hepatotoxicity was variable [14].

Although, many studies were conducted in different countries, they lack homogeneity on the magnitude and incidence of adverse effects of antiretroviral (ARV) drugs. This might be due to geographical and individual difference [15, 16]. In Ethiopia, there is few laboratory based researches done to understand the liver enzyme changes and the levels of elevation in patients taking ARV drug compared with treatment naïve controls. Therefore, this study was aimed to investigate liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital, Debre Berhan, Northeast Ethiopia.

Main text
Methods and materials
Study setting, population and sampling
Health institution based comparative cross sectional study was conducted from January to June 2015 at Debre Berhan Referral Hospital. The hospital is found at Debre Berhan town at a distance of 130 km from Addis Ababa, capital city of Ethiopia. Debre Berhan Referral Hospital provides different health service for about 2,045,992 people for North Shoa zone and people coming from neighboring regions like; Afar and Oromia [17]. ART service is one of the services that are provided by the hospital. During the study period, the hospital had 1527 HIV positive patients on HAART and 909 HIV positive patients on pre-ART.

Systematic sampling technique was applied to get a total sample size of 152 (76 people for each group). The sample size was estimated by double proportion formula through Epi-Info version 6 statistical packages by considering the risk of liver enzyme elevation on patients taking HAART was 2.5 times higher than the treatment naïve controls. The power of the study was assumed to be 80% at 95% confidence interval (CI) by allowing 5% margin of errors [18, 19].

Study variables and inclusion criteria
Dependent variables liver enzyme elevation (such as: ALT, AST, ALP, total protein, total and direct bilirubin). Liver enzyme elevation (Hepatotoxicity): operationally defined based on AIDS clinical trial group criteria or the Ethiopian ART guideline based on the serum ALT or AST values [2].

Independent variables demographic variables (age, sex, residence, education etc.).

Inclusion criteria volunteer respondents under HAART or pre-ART coming to the hospital during the data collection period and whose age ≥ 18 years were included in the study.

Exclusion criteria < 18 years old, clients who had known liver disease before HAART initiation, or individuals with hepatitis B or C virus positive were excluded

Ethical consideration
Ethical clearance was obtained from Addis Ababa University, College of Health Sciences ethical review committee. Permission was also requested and obtained from Debre Berhan Referral Hospital Manager and ART Focal person through a letter written from Addis Ababa University, College of Health Sciences. Data collection was started after we obtained written informed consent from each study participants.

Data collection and laboratory analysis
Demographic data were collected by using structured questionnaire through interview. 5 ml of whole blood was taken aseptically from pre-ART and ART patients by laboratory technologists. After formation of a clot, the serum was separated by centrifugation. Then the serum was screened for hepatitis B and C viruses to perform clinical chemistry parameters.

ALT, AST, ALP, total protein, total bilirubin, direct bilirubin, urea and creatinine tests were analyzed via Spain A25 Biosystem automated chemistry machine analyzer as per the manufacture instruction. The machine is controlled through software installed on dedicated PC that constantly informs the user about the status and progress of analyses (A25 Biosystem Spain, 2007). Fluorescence-activated cell sorter (FACS) (Becton–Dickinson, USA) was used to determine the absolute CD4+ T cells count. Hemoglobin was measured through hematology analyzer MindrayBC320 (Mindray Biomedical electronic Corporation, China). Before the laboratory analysis the
chemistry machine analyzer was calibrated and validated. In addition internal quality control was performed to maintain the quality of data.

### Statistical analysis

All data analyses were performed using SPSS version 21 software. Data were presented as means and calculations carried out using the Student’s independent t-test. Binary and multiple logistic regression models were utilized to assess associations of predictor variables and laboratory outcomes. p-value < 0.05 was taken as a cut point at 95% CI.

### Results

#### Demographic characteristics

A total of 152 individuals (76 HAART treated and 76 treatment naïve controls) were included in this study. The mean age of HAART treated groups and treatment naïve controls were 37.37 and 36.38 respectively. Most of the study participants were females and urban dwellers. More than half of the study participants had attended primary education and above (Table 1).

#### Laboratory results

Table 2 summarized the mean levels of liver enzymes between HAART treated group and treatment naïve controls and 95% CI for mean. HIV positive HAART treated group had significantly higher mean values of ALT, AST, ALP, total bilirubin and direct bilirubin when compared with treatment naïve controls. On the other hand, the mean values of total protein and creatinine level were significantly lower in patients taking HAART compared

| Parameter                  | Study group       | Number | Mean       | 95% CI for mean | p-value |
|----------------------------|-------------------|--------|------------|-----------------|---------|
| ALT (U/L)                  | ART group         | 76     | 35.67      | 32.18–39.16     | 0.000*  |
|                           | Pre-ART group     | 76     | 23.97      | 21.38–26.57     |         |
| AST (U/L)                  | ART group         | 76     | 36.05      | 32.88–39.23     | 0.000*  |
|                           | Pre-ART group     | 76     | 28.00      | 25.52–30.49     |         |
| ALP (U/L)                  | ART group         | 76     | 117.14     | 97.99–136.30    | 0.022*  |
|                           | Pre-ART group     | 76     | 89.45      | 75.27–103.64    |         |
| Total protein (g/dL)       | ART group         | 76     | 7.09       | 6.89–7.30       | 0.007*  |
|                           | Pre-ART group     | 76     | 7.46       | 7.29–7.64       |         |
| Total bilirubin (mg/dL)    | ART group         | 76     | 0.787      | 0.761–0.813     | 0.000*  |
|                           | Pre-ART group     | 76     | 0.660      | 0.649–0.673     |         |
| Direct bilirubin (mg/dL)   | ART group         | 76     | 0.275      | 0.227–0.324     | 0.007*  |
|                           | Pre-ART group     | 76     | 0.188      | 0.149–0.228     |         |
| Urea (mg/dL)               | ART group         | 76     | 19.945     | 18.414–21.477   | 0.875   |
|                           | Pre-ART group     | 76     | 19.750     | 17.824–21.678   |         |
| Creatinine (mg/dL)         | ART group         | 76     | 0.588      | 0.562–0.614     | 0.016*  |
|                           | Pre-ART group     | 76     | 0.641      | 0.607–0.675     |         |
| Hemoglobin (g/dL)          | Treatment group   | 76     | 15.44      | 14.98–15.91     | 0.245   |
|                           | Pre-ART group     | 76     | 15.02      | 14.46–15.58     |         |
| CD4 count (cells/µL)       | ART group         | 76     | 428.14     | 367.75–488.53   | 0.362   |
|                           | Pre-ART group     | 76     | 390.97     | 336.93–445.01   |         |

* Statistically significant
with treatment naïve controls. Urea, hemoglobin and CD4-T-cell count didn't show any significant difference between the two groups.

**Liver enzyme elevation**

In the current study, about 19 (25%) of the study participants of the HAART treated group and 7 (9.2%) of treatment naïve controls showed liver enzyme elevation. There was significant difference (p < 0.05) in the levels of liver enzyme elevation between the two groups with the odds of 3.095 (1.213, 7.898). In HAART treated groups 18 (23.7%) patients were developed mild liver enzyme elevation and also 1 (1.3%) patient developed moderate liver enzyme elevation.

**Association of independent variables with utilization of ARV therapy**

Nine independent variables were analyzed in multiple logistic regressions by considering the dependent variable ALT/AST level to understand their association. Out of nine independent variables that were analyzed in multiple logistic regressions, BMI was found statistically significant. Patient's whose body mass index (BMI) existed between 18.6 and 24.9 were 3 times more likely to developing ALT or AST elevation (Table 3).

**Discussion**

This study tried to evaluate the effect of HAART on liver enzyme elevation in patients taking HAART and treatment naïve controls. Liver enzyme elevation might be occurring through different causes like; drugs, toxins, HBV, BCV, HIV, endogenous metabolite and alcohol [15, 20–23]. Different ARV drugs have been reported to affect liver enzyme activity [24, 25]. The level of liver cell injury is usually assessed by measuring the plasma concentration of transaminase enzymes [26]. It is obvious that liver is the site of synthesis of thousands of enzyme. When there is any insult on liver, these enzymes were released into the plasma resulted in increased in concentration [27]. ALT and AST are the most sensitive indicators of liver cell injury and used for the diagnosis of acute hepatocellular disease [28].

There were significant differences (p < 0.05) in the mean values of ALT and AST between the two groups. This significant difference was explained due to the adverse effects of ARV drugs. ALT is a sensitive marker, primarily secreted in liver cells, while AST is produced in liver and other tissues like; heart, skeletal muscle, kidneys, brain, pancreas, lungs, leukocytes, and erythrocytes [27]. These enzymes are released into the plasma in greater amounts when there is an injury to the liver cell membrane resulting in increased permeability. Different research out puts indicated that patients taking ARV drugs had shown elevated levels of ALT and AST [28–30]. In this study, the mean value of ALP was significantly increased in HAART treated groups compared with treatment naïve controls. It is produced in the bile duct or near to the bile canicular membrane of hepatocytes, intestine, kidney, placenta and bone [27]. The observed significant difference in ALP might be due to the side effect of ARV drugs that leads to increased production of the liver ALP isoenzyme [28].

In this study, the mean value of total protein was significantly (p < 0.05) reduced in HAART treated groups compared to treatment naïve controls. The drop in protein synthesis in patients taking HAART might be due to drug induced hepatic damage that results in reduced synthesis of different plasma proteins [2, 31]. The mean levels of total and direct bilirubin were significantly (p < 0.05) increased in patients taking HAART compared with treatment naïve controls. This could be due to the effect of ARV drugs on liver that resulted in decreased processing of bilirubin [28]. Moreover, significantly lower mean level of creatinine was observed in HAART treated groups than treatment naïve controls, while the mean values of urea and hemoglobin were not statistically significant (p > 0.05) between the two groups.

In the current study, the overall liver enzyme elevation was 25% in patients taking HAART groups and 9.2% in treatment naïve controls. In this study severe form of liver enzyme elevation was not observed. However, different studies reported that ARV drugs resulted in different degrees of liver enzyme elevation or hepatotoxicity (such as; mild, moderate and severe). This might be due to a number of factors such as; co-infection with hepatitis virus, the habit of alcohol ingestion, the regime of the drug, the duration of treatment, presence or absence of comorbid conditions, geographic condition and genetic polymorphisms contributed for these differences in the level of liver injury among various studies [4, 6, 21, 32–37].

In this study, multiple logistic regression analysis of socio-demographic and clinical variables didn't show any statistical significant (p > 0.05) association on liver enzyme elevation based on (ALT/AST) values except BMI. Patients who had BMI between 18.5 and 24.9 were 3 times more likely to develop liver enzyme elevation (ALT/AST) than their counter parts. This might be due to the fact that BMI correlated with the drug metabolism properties of the patient [25, 33].

**Conclusion**

In this study, liver enzymes (ALT, AST, ALP, total protein, creatinine, total and direct bilirubin) were significantly elevated in patients taking HAART compared with treatment naïve controls. About 25% of patients taking HAART developed mild and moderate liver
enzyme elevation but 9.2% of treatment naïve controls developed mild liver enzyme alteration. As a result, regular clinical and laboratory monitoring will be necessary to prevent severe form of liver toxicity.

Table 3 Summarizing the association of independent variable with ALT/AST level via logistic regression analysis in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital, Northeast Ethiopia

| Variables            | ALT/AST Level | COR    | Sig     | AOR     |
|----------------------|---------------|--------|---------|---------|
|                      | Normal | Elevated |        |         |         |
| Age                  |         |         |        |         |         |
| ≤ 35 years           | 63 (41.4) | 14 (9.2) | 1 | 1 | 1 |
| > 35 years           | 63 (41.4) | 12 (7.9) | 1.167 (0.500–2.210) | 0.721 | 1.152 (0.438–3.031) |
| Sex                  |         |         | 1 | 1 | 1 |
| Male                 | 52 (34.2) | 9 (5.9) | 1 | 1 | 1 |
| Female               | 74 (48.7) | 17 (11.2) | 0.753 (0.312–1.821) | 0.529 | 1.255 (0.427–3.690) |
| Marital status       |         |         | 1 | 1 | 1 |
| Single               | 24 (15.8) | 4 (2.6) | 1 | 1 | 1 |
| Married              | 54 (35.5) | 15 (9.9) | 0.600 (0.180–1.998) | 0.405 | 0.510 (0.137–1.908) |
| Divorced             | 28 (18.4) | 3 (2) | 1.556 (0.316–7.652) | 0.587 | 1.947 (0.311–12.184) |
| Widowed              | 20 (13.2) | 4 (2.6) | 0.433 (0.140–1.338) | 0.813 | 1.019 (0.178–5.826) |
| Residence            |         |         | 1 | 1 | 1 |
| Urban                | 98 (64.5) | 23 (15.1) | 1 | 1 | 1 |
| Rural                | 28 (18.4) | 3 (2) | 2.190 (0.613–7.834) | 0.228 | 0.304 (0.072–1.280) |
| Educational status   |         |         | 1 | 1 | 1 |
| No formal education  | 23 (15.1) | 9 (5.9) | 0.249 (0.069–0.900) | 0.034 | 0.130 (0.029–0.592) |
| Primary education    | 62 (40.8) | 13 (8.6) | 0.465 (0.142–1.527) | 0.207 | 0.338 (0.092–1.242) |
| Secondary and above  | 41 (27) | 4 (2.6) | 1 | 1 | 1 |
| Clinical stage       |         |         | 1 | 1 | 1 |
| Stage I              | 45 (29.6) | 8 (5.3) | 1 | 1 | 1 |
| Stage II             | 30 (19.7) | 6 (3.9) | 0.889 (0.280–2.821) | 0.842 | 1.491 (0.364–6.108) |
| Stage III            | 42 (27.6) | 11 (7.2) | 0.679 (0.249–1.851) | 0.449 | 0.607 (0.193–1.908) |
| Stage IV             | 9 (5.9) | 1 (0.7) | 1.600 (0.178–14.42) | 0.675 | 1.635 (0.151–17.723) |
| Body mass index      |         |         | 1 | 1 | 1 |
| < 18.5               | 22 (14.5) | 9 (5.9) | 1 | 1 | 1 |
| 18.6–24.9            | 88 (57.9) | 15 (9.9) | 2.400 (0.929–6.201) | 0.071a | 3.387 (1.119–10.265) |
| ≥ 25                 | 16 (10.5) | 2 (1.3) | 3.273 (0.621–17.247) | 0.162 | 3.333 (0.536–20.733) |
| CPT-prophylaxis      |         |         | 1 | 1 | 1 |
| Yes                  | 61 (40.1) | 18 (11.8) | 0.417 (0.169–1.029) | 0.058 | 0.280 (0.093–0.842) |
| No                   | 65 (42.8) | 8 (5.3) | 1 | 1 | 1 |
| Regimens             |         |         | 1 | 1 | 1 |
| d4T-3TC-NVP          | 8 (10.5) | 2 (2.6) | 1.455 (0.212–9.984) | 0.703 | 2.710 (0.100–73.157) |
| d4T-3TC-EFV          | 2 (2.6) | 2 (2.6) | 0.364 (0.038–3.518) | 0.382 | 0.308 (0.003–3.145) |
| ZDV-3TC-NVP          | 16 (21.1) | 3 (3.9) | 1.939 (0.361–10.430) | 0.440 | 5.898 (0.287–121.288) |
| ZDV-3TC-EFV          | 11 (14.5) | 3 (3.9) | 1.212 (0.216–6.800) | 0.827 | 2.403 (0.133–43.467) |
| TDF-3TC-NVP          | 9 (11.8) | 5 (6.6) | 0.655 (0.134–3.186) | 0.600 | 0.519 (0.028–9.727) |
| TDF-3TC-EFV          | 11 (14.5) | 4 (5.3) | 1 | 1 | 1 |

COR crude odd ratio, AOR adjusted odds ratio, d4T stavudine, 3TC lamivudine, NVP nevirapine, EFV efavirenz, ZDV zidovudine, TDF tenofovir

a Multiple logistic regression statically significant, ALT normal value for male ULN ≤ 40 U/L, for female ALT ≤ 35 U/L and AST value for male ≤ 35 U/L and AST value for female ≤ 31 U/L

Limitation of the study
This comparative cross sectional study was becomes strong if the study design becoming a cohort. The study conducted on 152 study participants these number somewhat small to give an inference on the general population about the effects of HAART on liver
enzymes in patients taking HAART. Due to financial issues this study didn’t include all relevant liver enzymes that are employed for the diagnosis of liver injury (for instance γ-GGT).

Abbreviations
ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; Hb: hemoglobin; CD4+: cluster of differentiation; U/L: unit per liter; mg/dL: milligram per deciliter; g/dL: gram per deciliter; cells/µL: cells per micro liter; HAART: highly active antiretroviral therapy; ART: antiretroviral therapy; ULN: upper limit normal; WHO: world health organization; HIV: human immune deficiency virus; AIDS: acquired immuno deficiency syndrome; HBV: hepatitis B virus; HCV: hepatitis C virus; ANOVA: analysis of variance; AOR: crude odds ratio; ADR: adjusted odds ratio; CPT: cotrimoxazole preventive therapy; BMI: body mass index; CI: confidence interval; SPSS: statistical package for social sciences; Pt: protease inhibitor; d4T: stavudine; DNA: deoxynucleonic acid; FACS: Federal HIV/AIDS Prevention and Control Office; rpm: revolution per minutes; ECSA: Ethiopian central statistics agency; FACS: fluorescence-activated cell sorter.

Acknowledgements
The authors would like to acknowledge Mr. Demeke Endalamaw for his technical support during the laboratory analysis. We want to acknowledge Addis Ababa University, Department of biochemistry staff members. Finally, the authors also acknowledged the study participants for their valuable time and willingness to participate in this study.

Authors’ contributions
ET Involved in method development, data collection, blood sample analysis, data analysis and write up of the final manuscript. Similarly DS participated in method development, data analysis and write up of the final manuscript. YB and ZM also involved in method development, data analysis, write up of the final manuscript. All authors read and approved the manuscript.

Funding
Addis Ababa University, College of Health Science, Department of Biochemistry. The funding organization has no role in data collection, data analysis, data interpretation and manuscript writing.

Availability of data materials
All relevant data are included within the manuscript. If it is necessary it is possible to contact the corresponding author to get additional material.

Ethics approval and consent to participate
Ethical clearance was obtained from Addis Ababa University, College of Health Sciences ethical review committee. Permission was also requested and obtained from Debre Berhan Referral Hospital Manager through a letter written from Addis Ababa University, College of Health Sciences. We started the data collection after we obtained written informed consent from each study participants.

Consent of publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Biochemistry, College of Medicine and Health Sciences, Bahir Dar University, P.O. Box 79, Bahir Dar, Ethiopia. 2 Department of Biochemistry, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Received: 19 February 2019 Accepted: 18 October 2019 Published online: 30 October 2019

References
1. Khan K, Khan A, Sulaiman S, Soo C, Aftab R. Adverse effect of highly active anti-retroviral therapy (HAART) in HIV/AIDS patients. Indian J Pharm Pract. 2014. https://doi.org/10.5530/ijpp.7.3.7.
2. Federal HIV/AIDS Prevention and Control Office and Federal Ministry of Health (FHAPCO). Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. 2008. p. 77–80: http://www.who.int/hiv/pub/guidelines/ethiopia_art.
3. Pol S, Lebray P, Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004. https://doi.org/10.1086/381499.
4. Sulikowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182–9. https://doi.org/10.1053/hep.2002.30319.
5. Shepard K. Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]. Rigdefield. Boehringer Ingelheim Pharmaceuticals, 2004.
6. Sanine I, Mommje-Marin H, Hinkle J, Bartlett A, Lederman M, Maertens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005. https://doi.org/10.1086/428093.
7. Ena J, Amador C, Benito C, Fendell V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003;14(1):776–81. https://doi.org/10.1258/09564620360719840.
8. Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008;13(7):343–8.
9. Mbougou T, Laurent C, Kounanfack C, Bourgeois A, Ciaffi L, Calmy A, et al. Hepatotoxicity and effectiveness of a nevirapine based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health. 2010. https://doi.org/10.1186/1471-2458-10-105.
10. Andrade R, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega M, Lucena M. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol. 2007. https://doi.org/10.3748/wjg.v13.i3.329.
11. Soriano V, Puoti M, Garcia-Gasco P, Rockstroh J, Benhamoud Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1–13. https://doi.org/10.1097/QAD.0b013e3282d282ed.
12. Nii D, Osakunor M, Obinkoron C, Fianu V, Asare I, Dakorah M. Hepatic enzyme alterations in HIV patients on antiretroviral therapy: a case-control study in a hospital setting in Ghana. PLoS ONE. 2015;10(8):e0134449. https://doi.org/10.1371/journal.pone.0134449.
13. Shiferaw M, Tulu K, Zegeye A, Wubante A. Liver enzymes abnormalities among highly active antiretroviral therapy experienced and HAART naive HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: a comparative cross-sectional study. AIDS Res Treat. 2016. https://doi.org/10.1155/2016/1985452.
14. Fokunang C, Banin A, Kounanfack C, Ngogang J. Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active anti-retroviral therapy. J AIDS HIV Res. 2010;2(3):048–57.
15. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24(7):483–90.
16. Savita M, Singh B, Vengadakrishnan K, Damodharan J. Liver function abnormalities in human immunodeficiency virus positive individuals and its correlation with disease severity. Int J Sci Study. 2015;3(8):15–8. https://doi.org/10.13754/ijss/2015/499.
17. Ethiopian Central Statistics Agency (ECSA). Ethiopian Demographic and Health Survey report. 2011. p. 131. https://www.unicef.org/ethiopia/ET_2011_EDHS.
18. Degu G, Tessimma F. Lecture Notes for Health Science Students; University of Gondar In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education. 2005. p. 180–2. https://www.cartercenter.org/.
19. Abdissa S, Fekade D, Feleke Y, Sebota X, Dito E. Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital. Ethiop Med J. 2012;50(2):107–13.
20. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349(9055):825–32.
21. Hussaini SH, Farringtom EA. Idiosyncratic drug-induced liver injury; an overview. Expert Opin Drug Saf. 2007;6(6):673–84. https://doi.org/10.1517/14740338.6.6.673.
22. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47(11):1479–85. https://doi.org/10.1086/593104.
23. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26(S):511–8. https://doi.org/10.1089/aid.2009.0211.
24. Sułkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80.
25. Rose AU, Abraham OM, Bode JB, Abel NO. Risk factors for hepatotoxicity after introduction of highly active antiretroviral therapy. E&CG Hepatol. 2011;7(1–3):49–56.
26. Carlo T, Giuseppe L, Salvatore C, Massimo P, Mark N, Eugenia Q, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients; results from the Italian EPOKA-Master Cohort. BMC Infect Dis. 2005. https://doi.org/10.1186/1471-2334-5-58.
27. Burris CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnosis. 4th ed. Philadelphia: Elsevier Saunders Co; 2006.
28. Marc G, Jay HL, Fauci S, Braunwald E, Kasper L, Hauser L, Longo L, Jameson J, Llosalco J. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill Companies; 2008. p. 1918–2000.
29. Hernandez LV, Gilson I, Jacobson J, Affr A, Puetz TR, Dindzans VJ. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients. Aliment Pharmacol Ther. 2003;15(10):1627–32.
30. Hoffmann CJ, Charalambous S, Thi CL, Martin DJ, Pemb L, Fielding K, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21(10):1301–8. https://doi.org/10.1097/qad.0b013e32814e6b08.
31. Emejulu AA, Ujowundu CO, Igwe CJ, Ouwuliri VA. Hepatotoxicity of antiretroviral drugs in HIV seropositive Nigerian patients. Aust J Basic Appl Sci. 2010;4(9):4275–8.
32. Chu KH, Manzi M, Zuniga L, Biot M, Ford NR, Raschaert F, et al. Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique. Int J STD AIDS. 2012. https://doi.org/10.1258/ijjah.2009.009328.
33. Shicheng G, Xi-En G, Lipin D, Yongxi Z, Ke L, Rongrong Y, et al. Antiretroviral therapy hepatotoxicity: prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. Hepatol Res. 2010. https://doi.org/10.1111/j.1872-034x.2009.00608.
34. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Fuguen AK, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis. 2010;50(4):502–11. https://doi.org/10.1086/649922.
35. Kalyesubula R, Kagimu M, Opio C, Kiguba R, Semtala F, Schlech F, et al. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Africa Health Sci. 2011;11(1):16–23.
36. Núñez M, Daza B, Martin Carbonero L, Merino A. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(5):426–31.
37. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia; a prospective cohort study. Pharmacogenomics J. 2012;12(6):499–506. https://doi.org/10.1038/tjp.2011.34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.